{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:00:46Z","timestamp":1780574446095,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T00:00:00Z","timestamp":1465862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["tuberculosisjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.tube.2016.05.010","type":"journal-article","created":{"date-parts":[[2016,6,25]],"date-time":"2016-06-25T17:00:55Z","timestamp":1466874055000},"page":"S8-S11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"S1","title":["TB biomarkers, TB correlates and human challenge models: New tools for improving assessment of new TB vaccines"],"prefix":"10.1016","volume":"99","author":[{"given":"Stefan H.E.","family":"Kaufmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Fortune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Pepponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Ruhwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis K.","family":"Schrager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom H.M.","family":"Ottenhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2016.05.010_bib1","doi-asserted-by":"crossref","first-page":"a018523","DOI":"10.1101\/cshperspect.a018523","article-title":"Novel vaccination strategies against tuberculosis","volume":"4","author":"Andersen","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.tube.2016.05.010_bib2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.tube.2016.05.010_bib3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S2213-2600(15)00037-5","article-title":"Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial","volume":"3","author":"Ndiaye","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.tube.2016.05.010_bib4","doi-asserted-by":"crossref","first-page":"276fs8","DOI":"10.1126\/scitranslmed.aaa4730","article-title":"Tuberculosis vaccines: time for a global strategy","volume":"7","author":"Kaufmann","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tube.2016.05.010_bib5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coi.2014.01.009","article-title":"Challenges and responses in human vaccine development","volume":"28","author":"Kaufmann","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.tube.2016.05.010_bib6","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.5588\/ijtld.12.0246","article-title":"Enabling biomarkers for tuberculosis control","volume":"16","author":"Maertzdorf","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.tube.2016.05.010_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/ciu781","article-title":"Host immune response to tuberculous meningitis","volume":"60","author":"Visser","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2016.05.010_bib8","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.celrep.2014.11.023","article-title":"Mycobacterium tuberculosis proteome microarray for global studies of protein function and immunogenicity","volume":"9","author":"Deng","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.tube.2016.05.010_bib9","doi-asserted-by":"crossref","first-page":"a2052","DOI":"10.1136\/bmj.a2052","article-title":"Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial","volume":"337","author":"Hawkridge","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.tube.2016.05.010_bib10","doi-asserted-by":"crossref","first-page":"e1000782","DOI":"10.1371\/journal.ppat.1000782","article-title":"Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity","volume":"6","author":"Joosten","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.tube.2016.05.010_bib11","doi-asserted-by":"crossref","first-page":"e1004671","DOI":"10.1371\/journal.ppat.1004671","article-title":"Human CD8+ T-cells recognizing peptides from Mycobacterium tuberculosis (Mtb) presented by HLA-E have an unorthodox Th2-like, multifunctional, Mtb inhibitory phenotype and represent a novel human T-cell subset","volume":"11","author":"van Meijgaarden","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.tube.2016.05.010_bib12","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/eji.201445193","article-title":"Human CD8 T lymphocytes recognize Mycobacterium tuberculosis antigens presented by HLA-E during active tuberculosis and express type 2 cytokines","volume":"45","author":"Caccamo","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.tube.2016.05.010_bib13","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1128\/IAI.00287-09","article-title":"Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis","volume":"77","author":"Vordermeier","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.tube.2016.05.010_bib14","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.vaccine.2013.11.045","article-title":"Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines","volume":"32","author":"Dean","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.tube.2016.05.010_bib15","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1128\/CVI.00301-12","article-title":"Duration of immunity against Mycobacterium bovis following neonatal vaccination with bacillus Calmette-Gu\u00e9rin Danish: significant protection against infection at 12, but not 24, months","volume":"19","author":"Thom","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.tube.2016.05.010_bib16","doi-asserted-by":"crossref","first-page":"e1003077","DOI":"10.1371\/journal.ppat.1003077","article-title":"Global gene transcriptome analysis in vaccinated cattle revealed a dominant role of IL-22 for protection against bovine tuberculosis","volume":"8","author":"Bhuju","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.tube.2016.05.010_bib17","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1098\/rstb.2011.0091","article-title":"Vaccines against malaria","volume":"366","author":"Hill","year":"2011","journal-title":"Philos Trans R Soc Lond B"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979216301883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979216301883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T20:28:16Z","timestamp":1536611296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979216301883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":17,"alternative-id":["S1472979216301883"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2016.05.010","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TB biomarkers, TB correlates and human challenge models: New tools for improving assessment of new TB vaccines","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2016.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}